The current results indicated that autoSCT was capable of inducing long-term remission up to 16 years after treatment, but the outcome of patients with MCL who relapsed after autoSCT was poor, especially if their response duration after autoSCT was short. However, for a subset of patients with relapsed MCL, alloSCT may offer the possibility of durable survival, and individual patients can enjoy long-term survival after relapse even without undergoing alloSCT.
Department of Hematology, University of Heidelberg, Heidelberg, Germany. sascha.dietrich [at] med.uni-heidelberg.de
Cancer. 2011 May;117(9):1901-10
© Galenicom 1999-2013